#USA #Las Vegas #Viatris #Meloxicam #PAINWEEK

Viatris Showcases Five Key Presentations on MR-107A-02 at PAINWeek 2025

Viatris, a leading global healthcare organization, has made significant strides in acute surgical pain management. At the upcoming PAINWeek 2025 conference in Las Vegas, set to run from September 2-5, the company will present five abstracts highlighting the Phase 3 clinical trials of its innovative, fast-acting meloxicam formulation (MR-107A-02). This novel approach aims to provide effective pain relief while potentially reducing the reliance on opioids.

Key Highlights of the Presentations

The five presentations will delve into various aspects of MR-107A-02, detailing its efficacy, safety, and pharmacokinetic properties. Here's a breakdown of what to expect:

1. Pharmacokinetics Study: A comparative evaluation of MR-107A-02 and traditional meloxicam (Mobic®), assessing how quickly each formulation is absorbed by the body.
- Presentation Time: September 4, 4:35 PM - 4:45 PM PDT

2. Efficacy in Bunione​ctomy: Insights into the safety and effectiveness of MR-107A-02 for managing acute moderate-to-severe pain following bunion surgery.
- Presentation Time: September 4, 4:50 PM - 5:00 PM PDT

3. Efficacy in Herniorrhaphy: Demonstrating MR-107A-02's role in alleviating pain after hernia surgeries, aimed at enhancing patient comfort and recovery.
- Presentation Time: September 4, 5:05 PM - 5:15 PM PDT

4. Opioid Sparing Effects: A critical analysis of how MR-107A-02 can potentially minimize opioid use post-surgery, addressing a major concern in pain management today.
- Presentation Time: September 4, 5:20 PM - 5:30 PM PDT

5. Efficacy and Safety Summary: Presentation of comprehensive outcomes from studies focusing on acute postoperative pain management for both bunionectomy and herniorrhaphy using MR-107A-02.
- Format: Poster presentation only.

The Road Ahead

Viatris's commitment to health innovation is evident in its ongoing research into MR-107A-02. This fast-acting meloxicam formulation aligns with a broader mission to provide effective treatments while addressing the growing need for safer pain relief alternatives. The findings presented at PAINWeek 2025 will contribute significantly to our understanding of post-surgical pain management and open new avenues for patients suffering from acute pain.

About Viatris

Viatris (Nasdaq: VTRS) is not merely a pharmaceutical company but a global healthcare leader that combines the strengths of both generics and branded products. Focused on making the world healthier, Viatris provides access to high-quality medicines for nearly 1 billion patients globally each year. With a robust portfolio and innovative global supply chain, Viatris is dedicated to addressing diverse health challenges at every stage of life.

To learn more about Viatris and their commitment to improving healthcare, visit viatris.com.

Concluding Thoughts

The presentations at PAINWeek 2025 offer a glimpse into the future of pain management, emphasizing the need for rapid-acting and safer alternatives in the wake of the opioid crisis. With innovative solutions like MR-107A-02, Viatris is poised to influence the landscape of surgical pain relief positively.